 |
14 Diseases |  |
10 Trials |
|
10 Trials |  |
201 News |  |
| «1234 |
- Intuniv (guanfacine XR) / Shionogi, Takeda
Trial termination: Effect of Guanfacine Extended-Release on Attention Deficit Hyperactivity Disorder (ADHD)-Associated Insomnia (clinicaltrials.gov) - Mar 28, 2012
P4, N=32, Terminated, Sponsor: Children's Specialized Hospital
Recruiting --> Terminated; extended beyond completion date; chose to close out rather than renew IRB review
- Intuniv (guanfacine XR) / Shionogi, Takeda
Enrollment change: Effect of Guanfacine Extended-Release on Attention Deficit Hyperactivity Disorder (ADHD)-Associated Insomnia (clinicaltrials.gov) - Mar 28, 2012
P4, N=32, Terminated, Sponsor: Children's Specialized Hospital
Recruiting --> Terminated; extended beyond completion date; chose to close out rather than renew IRB review N=40 --> 32
- | Intuniv (guanfacine XR) / Shionogi, Takeda
New P4 trial: Guanfacine in Children With Tic Disorders (clinicaltrials.gov) - Feb 29, 2012
P4, N=42, Recruiting, Sponsor: Yale University
- Intuniv (guanfacine XR) / Shionogi, Takeda
Enrollment change: Electrophysiological Effects of Guanfacine Extended Release in Attention Deficit Hyperactivity Disorder (ADHD) (clinicaltrials.gov) - Feb 14, 2012
P4, N=42, Completed, Sponsor: The University of Texas Health Science Center at San Antonio
N=40 --> 32 N=60 --> 42
- Intuniv (guanfacine XR) / Shionogi, Takeda
Trial completion: Electrophysiological Effects of Guanfacine Extended Release in Attention Deficit Hyperactivity Disorder (ADHD) (clinicaltrials.gov) - Feb 14, 2012
P4, N=42, Completed, Sponsor: The University of Texas Health Science Center at San Antonio
N=60 --> 42 Recruiting --> Completed
- Intuniv (guanfacine XR) / Shionogi, Takeda
Enrollment open: Guanfacine for the Treatment of Hyperactivity in Pervasive Developmental Disorder (clinicaltrials.gov) - Feb 12, 2012
P4, N=112, Recruiting, Sponsor: Yale University
Recruiting --> Completed Not yet recruiting --> Recruiting
- |||||||||| Intuniv (guanfacine XR) / Shionogi, Takeda
New P3 trial: Access to Extended Release Guanfacine HCl for Subjects Who Participated in Studies SPD503-315 or SPD503-316 in Europe (clinicaltrials.gov) - Dec 26, 2011
P3, N=249, Active, not recruiting, Sponsor: Shire
- | Intuniv (guanfacine XR) / Shionogi, Takeda
New P2 trial: SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP) (clinicaltrials.gov) - Nov 9, 2011
P2, N=83, Completed, Sponsor: Shire Development LLC
- Intuniv (guanfacine XR) / Shionogi, Takeda
New P1 trial: Open-Label Pilot Study of Guanfacine-Extended Release for the Treatment of Cannabis Dependence (clinicaltrials.gov) - Nov 7, 2011
P1, N=20, Recruiting, Sponsor: New York State Psychiatric Institute